Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy
Abstract Background Chemotherapy‐induced peripheral neuropathy (CIPN) is a significant and difficult to manage side effect of neurotoxic chemotherapies. Several risk factors for CIPN have been identified to date, but inconsistencies and methodological limitations exist in past research. Also, a limi...
Main Authors: | Alex Molassiotis, Hui Lin Cheng, Kwun To Leung, Yu Chung Li, Kam Hung Wong, Joseph Siu Kie Au, Raghav Sundar, Alexandre Chan, Terrence Rong De Ng, Lorna K. P. Suen, Choi Wan Chan, Janelle Yorke, Violeta Lopez |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-06-01
|
Series: | Brain and Behavior |
Subjects: | |
Online Access: | https://doi.org/10.1002/brb3.1312 |
Similar Items
-
Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy
by: Alex Molassiotis, et al.
Published: (2019-02-01) -
Primary Squamous Cell Carcinoma of Breast Responsive to Platinum and Taxane-Based Chemotherapy: A Rare Entity and Review Literature
by: Jagjit K. Pandey, et al.
Published: (2020-07-01) -
Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients
by: Jalid Sehouli, et al.
Published: (2021-09-01) -
Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers
by: Tibor A. Zwimpfer, et al.
Published: (2024-01-01) -
Cell death in cancer chemotherapy using taxanes
by: Ana P. Xu, et al.
Published: (2024-01-01)